Unichem Laboratories Ltd

Unichem Labs. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Unichem Laboratories Ltd

₹ 594 2.35%
26 Apr - close price
unichemlabs.com BSE: 506690 NSE : UNICHEMLAB
About

Unichem Laboratories Ltd is involved in pharmaceuticals
in Generics, APIs and Contract Manufacturing (CMO) areas.[1]

Key Points

Therapeutic Areas
The company manufactures a wide range of APIs and pharmaceutical formulations as branded and simple generics. Its products cater to diverse range of therapeutic areas, such as cardiology, gastroenterology, diabetology, psychiatry, neurology and others. [1]

Website BSE NSE
  • Market Cap ₹ 4,186 Cr.
  • Current Price ₹ 594
  • High / Low ₹ 607 / 365
  • Stock P/E
  • Book Value ₹ 332
  • Dividend Yield 0.00 %
  • ROCE -5.98 %
  • ROE -7.77 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company is almost debt free.
  • Company is expected to give good quarter

Cons

  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of 9.99% over past five years.
  • Company has a low return on equity of -2.51% over last 3 years.
  • Company has high debtors of 161 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
311 261 201 217 248 277 245 266 252 310 347 334 362
280 233 230 227 265 264 256 297 294 319 338 341 343
Operating Profit 32 28 -29 -10 -17 12 -11 -31 -42 -9 8 -7 19
OPM % 10% 11% -14% -5% -7% 5% -4% -12% -17% -3% 2% -2% 5%
13 5 13 5 15 9 12 6 15 -104 6 8 78
Interest 1 0 0 1 0 1 2 3 2 3 2 4 2
Depreciation 19 20 20 20 21 21 23 26 29 28 27 27 26
Profit before tax 26 12 -36 -27 -24 -0 -23 -55 -57 -144 -16 -31 69
Tax % -19% 93% 24% 19% 0% 6,289% 0% -38% 0% 0% 0% 0% 0%
30 1 -28 -21 -24 17 -23 -75 -57 -144 -16 -31 69
EPS in Rs 4.32 0.12 -3.95 -3.04 -3.34 2.46 -3.31 -10.72 -8.11 -20.43 -2.23 -4.38 9.84
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
803 1,005 1,044 1,091 1,221 576 666 968 904 1,124 943 1,072 1,353
676 819 863 989 1,078 813 798 1,019 994 1,028 986 1,165 1,341
Operating Profit 127 186 181 102 142 -237 -132 -52 -89 95 -43 -93 12
OPM % 16% 18% 17% 9% 12% -41% -20% -5% -10% 8% -5% -9% 1%
9 14 84 20 19 366 2,737 94 98 47 42 -71 -12
Interest 3 2 2 2 2 2 3 1 1 1 2 9 12
Depreciation 28 35 43 38 35 39 45 62 71 76 83 106 109
Profit before tax 105 162 220 82 124 87 2,556 -20 -64 66 -87 -279 -121
Tax % 22% 20% 20% 21% 19% -19% -0% 144% 12% 18% 36% -7%
82 130 177 64 100 104 2,557 9 -56 54 -55 -300 -121
EPS in Rs 9.13 14.33 19.52 7.09 11.06 11.43 363.48 1.25 -8.00 7.68 -7.87 -42.57 -17.20
Dividend Payout % 33% 31% 41% 28% 18% 26% 1% 320% -50% 52% -51% -9%
Compounded Sales Growth
10 Years: 1%
5 Years: 10%
3 Years: 6%
TTM: 30%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 40%
Stock Price CAGR
10 Years: 11%
5 Years: 25%
3 Years: 19%
1 Year: 59%
Return on Equity
10 Years: 13%
5 Years: -2%
3 Years: -3%
Last Year: -8%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 18 18 18 18 18 18 14 14 14 14 14 14 14
Reserves 712 795 888 929 1,009 1,113 2,748 2,718 2,633 2,683 2,658 2,370 2,323
48 6 1 0 8 1 0 0 17 1 132 108 121
248 314 300 274 306 371 346 298 361 420 318 394 337
Total Liabilities 1,026 1,133 1,207 1,222 1,342 1,503 3,108 3,030 3,025 3,119 3,122 2,886 2,796
385 426 394 396 381 468 555 789 829 850 963 1,236 1,209
CWIP 111 129 86 119 233 247 236 90 331 568 494 148 122
Investments 106 140 120 153 111 89 979 1,042 668 520 390 41 41
424 437 607 555 617 698 1,338 1,109 1,197 1,181 1,275 1,462 1,423
Total Assets 1,026 1,133 1,207 1,222 1,342 1,503 3,108 3,030 3,025 3,119 3,122 2,886 2,796

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
129 180 87 88 117 141 -66 -251 -42 -33 -158 -117
-111 -127 35 -62 -87 -132 1,648 -323 -36 -73 104 241
-15 -51 -98 -47 -39 -9 -930 -45 -21 -45 96 -62
Net Cash Flow 3 3 24 -21 -9 -0 653 -619 -98 -150 42 62

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 84 77 74 69 79 188 127 125 130 117 147 161
Inventory Days 175 127 183 159 162 371 216 242 301 326 438 335
Days Payable 169 153 149 122 153 334 220 170 199 159 150 170
Cash Conversion Cycle 89 51 108 106 88 225 123 197 233 284 436 325
Working Capital Days 84 62 102 95 100 233 190 222 221 208 286 268
ROCE % 14% 20% 19% 9% 13% -8% 132% -0% -2% 2% -3% -6%

Shareholding Pattern

Numbers in percentages

Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
50.93% 50.93% 50.93% 50.93% 50.93% 50.94% 50.94% 50.94% 50.94% 70.21% 70.22% 70.22%
1.54% 1.53% 1.45% 1.47% 1.50% 1.71% 1.56% 1.70% 1.62% 0.83% 0.84% 0.90%
9.09% 9.09% 9.30% 9.59% 9.53% 8.70% 8.21% 8.15% 9.65% 10.00% 10.46% 11.26%
38.43% 38.44% 38.32% 38.01% 38.04% 38.67% 39.31% 39.21% 37.80% 18.95% 18.47% 17.63%
No. of Shareholders 34,25833,89235,31333,55732,66629,57330,61829,41826,64221,58420,87721,171

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls